Design of two phase III open-label trials evaluating ocrelizumab in patients with relapsing-remitting multiple sclerosis and suboptimal response to disease-modifying treatment

Bermel R., Comi G., Eralinna J. -., Leist T. P., Nicholas R., Oreja-Guevara C., ...More

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Canada, 14 - 17 September 2016, vol.22, pp.615-616 identifier

  • Publication Type: Conference Paper / Summary Text
  • Volume: 22
  • City: London
  • Country: Canada
  • Page Numbers: pp.615-616
  • Istanbul University Affiliated: Yes